LXRX — LEXICON PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1062822 ·
Last close
$1.78
Market Cap
$792.52M
52W High
$2.68
52W Low
$1.10
ADV30
2,109,137
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 692,000 | 653,000 | -26,540,000 | -31,775,000 | 250,060,000 | 40,924,000 | 75,535,000 |
| Mar 2026 | 21,102,000 | 20,994,000 | -996,000 | -1,043,000 | 268,819,000 | 38,089,000 | 65,963,000 |
| Dec 2025 | 5,493,000 | 5,292,000 | -14,780,000 | -15,530,000 | 184,987,000 | 34,326,000 | 77,449,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,988,000
Investing CF
$-29,769,000
Financing CF
$85,317,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.14
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,050,401,000
Inventory
$1,196,000
Receivables
$1,643,000
ST Investments
$149,686,000
EBIT TTM
$-52,732,000
Pretax Income TTM
$-61,117,000
Interest Exp TTM
$8,385,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$41,469,000
EBITDA
$-54,023,000
Free Cash Flow
$-44,774,624
Enterprise Value
$527,165,792
Total Cash
$190,610,000
Total Debt
$59,241,000
Shares Out
445,234,571
Trailing EPS
$-0.15
Book Value
$0.30
ROE
-40.2%
ROA
-14.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 49,803,000 | -48,911,000 | -50,341,000 | 184,987,000 | 77,449,000 | 107,538,000 | -67,851,000 |
| Dec 2024 | 31,081,000 | -197,117,000 | -200,403,000 | 298,420,000 | 152,470,000 | 145,950,000 | -178,780,000 |
| Dec 2023 | 1,204,000 | -171,750,000 | -177,119,000 | 229,429,000 | 136,319,000 | 93,110,000 | -161,897,000 |
| Dec 2022 | 139,000 | -100,760,000 | -101,944,000 | 194,299,000 | 77,175,000 | 117,124,000 | -88,851,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$41,469,000
NetIncome TTM
$-61,116,000
OpCashFlow TTM
—
Assets (Latest)
$250,060,000
Forward EPS
$-0.19
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $1.72 · call volume: 96 · put volume: 212
Expected Move to 2027-01-15:
±$0.55
(31.98%) —
implied range
$1.17 –
$2.27
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $793.98M | $25.55 | — |
| ARDX | ARDELYX, INC. | $799.36M | $3.18 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $806.23M | $4.87 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $808.18M | $42.92 | — |
| IVA | Inventiva S.A. | $760.63M | $3.22 | — |
News headlines (Yahoo Finance, 1h cache)
Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
2026-11-11 13:30 · Yahoo
New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
2026-11-09 13:30 · Yahoo
What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call
2026-11-06 09:14 · Yahoo
Lexicon (LXRX) Q3 2026 Earnings Call Transcript
2026-11-05 19:16 · Yahoo
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates
2026-11-05 13:35 · Yahoo
Lexicon: Q3 Earnings Snapshot
2026-11-05 12:22 · Yahoo
Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
2026-11-05 12:00 · Yahoo
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
2026-10-29 12:30 · Yahoo
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
2026-10-23 12:30 · Yahoo
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
2026-09-28 21:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.